Article

Depression Linked with Cognitive Impairment in New-Onset Lupus

Depression is associated with significantly poorer cognitive function in patients with a new diagnosis of systemic lupus erythematosus (SLE) as well as in patients with established disease. Intervention trials of antidepressants for a Calgary Depression Scale (CDS) score higher than 6 are clearly indicated in depressed patients with SLE who have cognitive impairment.

Depression is associated with significantly poorer cognitive function in patients with a new diagnosis of systemic lupus erythematosus (SLE) as well as in patients with established disease. Intervention trials of antidepressants for a Calgary Depression Scale (CDS) score higher than 6 are clearly indicated in depressed patients with SLE who have cognitive impairment.

Petri and colleagues performed cognitive function testing (Automated Neuropsychological Assessment Metrics [ANAM]) in 111 patients known to have SLE for less than 9 months. The CDS was used to measure depression.

Slightly fewer than one-third (31%) of the study participants were depressed-as indicated by a CDS score higher than 6-an incidence similar to that found among persons with long-standing SLE. The depressed patients were clinically and demographically similar to the other study participants but were more likely to have fibromyalgia and fatigue. Like persons with prolonged SLE, the depressed persons performed poorly on ANAM throughput measures of continuous performance, simple reaction time, and memory. Depression was not linked with poor performance on mathematical or spatial processing tests.

The authors suggested that future studies be directed toward investigating whether management of depression improves cognitive impairment and exploring the neurological mechanisms.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
© 2025 MJH Life Sciences

All rights reserved.